OPT

Opthea

Pharmaceuticals, Biotechnology & Life Sciences

Opthea is a biopharmaceutical company focused on developing innovative biologics-based therapies for treating vision-threatening eye diseases. The company is pioneering the development of sozinibercept, a first-in-class VEGF-C/D 'trap' inhibitor, aimed at improving treatment outcomes for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Pharmaceuticals

Biotechnology

Eye Disease

Drug Development

Shorted

short percentage2.90%

reported shorts39.6M

shares on issue1.368B

Shorted

short percentage

reported short positions

total shares on issue

About

website

opthea.com

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

Suite 0403, Level 4, 650 Chapel Street, SOUTH YARRA, VIC, AUSTRALIA, 3141

Connect

Key Metrics

market cap

$820.79M

eps$-0.43

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

Pharmaceuticals

Biotechnology

Eye Disease

Drug Development

Innovation

Company Overview

AI-generated company summary

Company History

Opthea was founded with the mission to improve the lives of individuals affected by blinding eye diseases. Over the years, the company has focused on developing novel therapies, with its lead product candidate, sozinibercept, currently in Phase 3 development. Opthea aims to be the first in 20 years to introduce a new therapy that significantly enhances the quality of life for patients with wet AMD.

Competitive Advantages

Opthea's competitive advantages include its focus on biologics-based therapies, its pioneering approach with sozinibercept as a VEGF-C/D 'trap' inhibitor, and its commitment to addressing unmet needs in the treatment of wet AMD and DME.

Risk Factors

•Regulatory approval challenges
•Clinical trial risks
•Market competition

Recent Developments

Last 6 months

Opthea has been advancing its lead product candidate, sozinibercept, through Phase 3 clinical trials, aiming to establish it as a new standard in the treatment of wet AMD.

Key People

Leadership team at Opthea

Jeremy M. Levin

Chair

Jeremy M. Levin serves as the Chairman of the Board at Opthea, bringing extensive experience in the pharmaceutical industry.

Kathy Connell, GAICD

Non-Executive Director

Kathy Connell is a Non-Executive Director and Chair of the Remuneration Committee, contributing her expertise in governance and strategic oversight.